Insights On Pharmaceutical Production

  1. The Future Of Highly Potent API Manufacturing - Lonza Perspective 5/7/2020

    Highly potent active pharmaceutical ingredients (HPAPIs) represent an increasing fraction of new compounds in pharmaceutical pipelines today. Flexible and phase-appropriate infrastructure is needed to bring the next innovative medicines based on these challenging compounds from concept to commercialization. Thispresentation describes Lonza's HPAPI "manufacturing 4.0" investments and the company's innovative capabilities.

  2. Addressing New Chromatography Challenges With Fiber Absorbents 6/2/2019

    An absorbent material using a novel proprietary structure overcomes the diffusional and flow limitations of packed bed chromatography purification systems and aims to address the capacity issues.

  3. An Executive’s Checklist For CDMO Selection 10/30/2020

    C-level executives must take an early and active role in vetting potential partners using a deeper understanding of the capabilities and characteristics a CDMO should have to successfully bring a product to market.

  4. Virus Reduction Of An Affinity Capture Step: Viral Clearance For Protein A 5/17/2019

    Learn more about how HiScale 10/40, packed with MabSelect PrismA, is a reliable choice for the capture step in a virus clearance study.

  5. HFC Single-Use Sterile Disconnections 12/9/2020

    With a simple push of the thumb latch, sterility is maintained on both sides of the system during the disconnection process. Product Manager Maria Bollensen shows how easy it is.

  6. 6 Critical Considerations For Bioprocess Lab Equipment Selection 10/31/2019

    As pharma requires more open and flexible systems, special attention should be paid to selection criteria and how bioprocess equipment meets present and future requirements.

  7. Downstream Processing Of Biosimilars: Evolving Challenges And Considerations 1/11/2021

    Future evolutions in the biosimilar regulatory pathway will require biosimilar manufacturers to ask several critical questions about the implementation of legacy and novel technologies and procedures in downstream processing.

  8. Does Your CDMO Have Sustainable API And RSM Strategies? 10/9/2020

    To prevent costly delays in your timeline, you must be sure the CDMO you select has appropriate oversight of their RSM and API manufacturing supply chain.

  9. Navigate The CMC Regulatory Landscape For Cell And Gene Therapies 10/9/2020

    The curing potential of cell and gene therapies is driving the industry to gain a better understanding of the evolving regulatory guidelines for these products, in order to bring them to market faster.

  10. Telltale Signs You’re With The Wrong CDMO 4/27/2020

    Is your CDMO an asset or a hindrance? This article explores 10 red flags that signal your parter isn't carrying its weight on your journey to commercialization.